DMK PHARMACEUTICALS CORPORATION

NASDAQ: DMK (DMK Pharmaceuticals Corporation)

Last update: 15 hours ago

0.609

0.00 (-0.60%)

Previous Close 0.613
Open 0.610
Volume 64,274
Avg. Volume (3M) 1,228,320
Market Cap 6,147,611
52 Weeks Range
0.450 (-26%) — 21.70 (3463%)
Earnings Date 14 Nov 2023

AIStockmoo Score

0.0
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Financial Health info NA
Earnings Trend info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
From our AI technical analysis of the chart. info NA
Trend Strength info NA
Technical Setup info NA
Candle Patterns info NA
Medium-Term Trend info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Insider Activity info NA
Institutional Flow info NA
Short Interest info NA
Market environment cautious. info
Sector outperforming the market.
No pillar has a clear reading, so the score is unchanged.
Price Volatility info NA
No clear trend across the short, medium and long term. info
No clear signal from support and resistance. info
Final Score 0.00
Show all

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock DMK Pharmaceuticals Corporation - -

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
DMK 6 M - - - 0.0
SUPN 6 B 27.84% - 1.59 -1.0
ANIP 2 B - 13.74 2.57 -0.1
COLL 783 M - 23.13 2.72 0.1
TKNO 480 M - - - 0.8
AQST 435 M - - - -1.7

Select this tab to load the latest available analysis.

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Value

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria